Corporate ActionJun 22, 2026, 09:21 AM
Aethlon Medical Announces $12M Public Offering of Stock and Warrants
AI Summary
Aethlon Medical, Inc. filed an S-1 registration statement for a best-efforts public offering of up to 6,000,000 shares of common stock and accompanying warrants, aiming to raise up to $12,000,000. The offering price is $2.00 per unit, with estimated net proceeds of $11,220,000 before expenses. The company also provided updates on its Hemopurifier device, including progress in its Australian oncology trial, pre-clinical research, and its FDA Breakthrough Device designation for cancer and viral infections.
Key Highlights
- Public offering of up to 6,000,000 common shares and warrants.
- Combined public offering price set at $2.00 per share/warrant.
- Maximum gross proceeds from offering estimated at $12,000,000.
- Estimated net proceeds to company are $11,220,000 before expenses.
- Placement agent fees include 6.5% cash and 4.0% warrants.
- Australian oncology trial Cohort 3 enrollment initiated.
- R&D costs were $1.912M in FY2026 and $2.212M in FY2025.
- Company holds 4 US patents, 27 foreign patents, and 18 pending applications.
Price Impact
More from AEMD